A multicenter retrospective observational study assessing the prevalence of potential drug-drug interactions between investigational/ approved medications for managing COVID-19 (COVID-meds) and co- medicationsof hospitalized COVID-19 patients
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Azithromycin (Primary) ; Dexamethasone (Primary) ; Hydroxychloroquine (Primary) ; Interferon beta-1b (Primary) ; Lopinavir/ritonavir (Primary) ; Remdesivir (Primary) ; Tocilizumab (Primary) ; Antiplatelets; Heparin
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- 22 Apr 2021 New trial record
- 10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections